Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Biomarker Testing and DNA Collection in Subjects Participating in a Double-Blind, Placebo-Controlled, Crossover, Flexible-Dose Evaluation of the Efficacy, Safety, and Tolerability of STX209 in the Treatment of Irritability in Subjects With Fragile X Syndrome

NCT00823368 is registered in ClinicalTrials.gov with Seaside Therapeutics, Inc. as lead sponsor.

NCT NCT00823368
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00823368 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Biomarker Testing and DNA Collection in Subjects Participating in a Double-Blind, Placebo-Controlled, Crossover, Flexible-Dose Evaluation of the Efficacy, Safety, and Tolerability of STX209 in the Treatment of Irritability in Subjects With Fragile X Syndrome
Lead sponsor
Seaside Therapeutics, Inc.
Phase
Observational
Overall status
Completed
Start date
January 31, 2009
Completion date
Not reported
Enrollment
Not reported
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

fragile x syndrome